Thursday 15 October 2026
Export IVVD’s income statement to Excel — free account
Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.67
0.06
+9.84%
Follow IVVD
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 0.00 | 7.96 |
Altman Z-Score |
— | — | — | — | — | (13.19) | 2.85 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (28.78) | (0.36) |
Beneish M-Score |
— | — | — | — | — | — | (1.63) |
P/Operating CF |
— | — | — | — | — | (1.39) | (27.52) |
P/B ratio |
— | — | — | — | — | 0.77 | 1.76 |
Price to Tangible BV |
— | — | — | — | — | 0.77 | 1.76 |
EV/Sales |
— | — | — | — | — | 0.00 | 3.72 |
EV/EBITDA |
— | — | — | — | — | 0.10 | 0.00 |
EV/Operating CF |
— | — | — | — | — | 0.10 | (3.42) |
EV/FCF |
— | — | — | — | — | 0.10 | (3.41) |
Quick Ratio |
— | 8.80 | 9.53 | 14.88 | 3.99 | 1.29 | 7.04 |
Current Ratio |
— | 8.98 | 9.94 | 15.06 | 4.47 | 1.62 | 7.24 |
Net Debt/EBITDA |
— | 1.76 | 2.62 | 1.49 | 0.95 | 0.40 | 4.24 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.26 |
Operating CF/Net income |
— | 0.22 | 0.81 | 0.91 | 0.87 | 1.00 | 1.11 |
Capex/Depreciation |
— | — | (0.06) | 1.09 | (0.68) | (0.04) | (0.07) |
| — | (26.51%) | (92.05%) | (52.81%) | (74.48%) | (138.71%) | (33.96%) | |
| — | (111.29%) | (61.50%) | (48.11%) | (64.88%) | (94.75%) | (25.83%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (233.82%) |
Return on Tangible Assets |
— | (62.62%) | (40.88%) | (68.14%) | (112.55%) | (422.56%) | (24.45%) |
Average Days of Receivables |
— | — | — | 0.00 | — | 156.82 | 95.09 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 540.71% | 71.70% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 249.72% | 125.28% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 77.95% | 21.79% |
Graham Net Nets |
— | — | — | — | — | 0.74 | 0.50 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | (327.27%) | (12.96%) |
Free Cash Flow Yield |
— | — | — | — | — | (327.10%) | (13.70%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.31 |
Operating CF per Share |
— | (4.04) | (4.33) | (2.03) | (1.58) | (1.44) | (0.34) |
Capex per Share |
— | 0.00 | 0.00 | (0.02) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (4.04) | (4.34) | (2.05) | (1.59) | (1.44) | (0.34) |
Cash per Share |
— | 31.87 | 13.88 | 3.44 | 1.83 | 0.59 | 1.32 |
Shareholders Equity per Share |
— | (18.08) | 13.09 | 3.29 | 1.62 | 0.57 | 1.40 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (18.08) | 13.09 | 3.29 | 1.62 | 0.57 | 1.40 |
Free Cash Flow |
— | (14.57) | (184.82) | (221.69) | (173.78) | (170.63) | (58.29) |
Working Capital |
— | 104.31 | 554.65 | 351.89 | 174.59 | 38.71 | 213.30 |
Capital Expenditures |
— | — | (0.08) | (1.70) | (0.61) | (0.14) | (0.15) |
Net Current Asset Value |
— | (65.25) | 554.64 | 349.72 | 173.17 | 38.71 | 212.12 |
EV/EBIT |
— | — | — | — | — | 0.10 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | — | 17.24 | (0.68) | 0.48 | 2.06 | 1.54 |
Cash ROIC |
— | (29.29%) | (16.08%) | (30.45%) | (45.96%) | (124.65%) | (12.45%) |
Accounts Receivable Turnover |
— | — | — | — | — | 4.50 | 4.30 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.13 | 0.00 | 0.18 | 0.31 |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 2,110,795.00 | 1,198.50 | 0.00 | 2,356.93 | 1,338.82 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | — | 5.64 | 12.41 |
Average Payables |
— | 6.97 | 6.97 | 3.65 | 4.74 | 9.20 | 12.10 |
Average Assets |
— | 58.69 | 368.74 | 501.63 | 306.17 | 179.35 | 203.20 |
Average Common Equity |
— | 246.39 | 246.39 | 456.99 | 266.72 | 122.50 | 154.54 |
Columns are period end dates